Biopharma

Why Clear wants in on health care

In this edition of STAT's Health Tech newsletter: Why Clear wants to get into th...

Blue Laser Vaporization Effective for Benign Prostatic ...

TUESDAY, April 8, 2025 -- Blue laser vaporization alleviates lower urinary trac...

Semaglutide Ups Risk for Nonarteritic Anterior Ischemic...

TUESDAY, April 8, 2025 -- For patients with diabetes, semaglutide use is associ...

Globally, One in 13 Youth Experience Nocturnal Enuresis

TUESDAY, April 8, 2025 -- One in 13 youth and adolescents globally experience n...

Narrowband UVB Phototherapy Underused for Pediatric Vit...

TUESDAY, April 8, 2025 -- Narrowband UVB (nbUVB) phototherapy may be underutili...

mHealth-Supported Intervention Boosts Physical Activity...

TUESDAY, April 8, 2025 -- A mobile health (mHealth)-supported home-delivered ph...

Rural-Urban Differences Seen in Cardiometabolic Risk Fa...

TUESDAY, April 8, 2025 -- There are substantial rural-urban disparities in card...

AAN: Tavapadon as Adjunct to Levodopa Ups Daily ON Time...

TUESDAY, April 8, 2025 -- For patients with Parkinson disease with motor fluctu...

USPSTF Recommends Primary Care Interventions to Support...

TUESDAY, April 8, 2025 -- The U.S. Preventive Services Task Force (USPSTF) reco...

Fierce Biotech Layoff Tracker 2025: Tango Tx trims team...

As always, if you know of layoffs occurring at a biotech, please reach out to th...

US risks losing biotech edge to China, report warns

“There will be a ChatGPT moment for biotechnology,” a bipartisan commission wrot...

STAT+: RFK Jr.’s Senate hearing delayed, living with mo...

This week in health care policy and politics: RFK Jr.'s hearing delayed, measles...

Rallybio discontinues lead drug for rare maternal disorder

The company has decided to switch gears following disappointing data for a monoc...

FDA clears vibrating mattress pad to stimulate breathin...

Prapela’s device provides gentle, randomized movements that aim to trigger and r...

Rallybio discontinues lead candidate for rare maternal ...

The company has decided to switch gears following disappointing data for a monoc...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Loqtorzi, Toripalimab,...

Rocket boosts preparations for gene therapy launch with...

As the countdown to the launch of its first therapeutic continues, Rocket Pharma...

RFK Jr. promotes measles vaccine as Texas outbreak cont...

The HHS secretary called out the measles vaccines as "the most effective way" to...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Kentera (previously Ox...

Human medicines European public assessment report (EPAR...

Human medicines European public assessment report (EPAR): Azilect, rasagiline, D...

Congressional commission urges $15B, more action to mai...

A U.S. congressional commission has made the case for “swift action” to maintain...

STAT+: As more patients get automated test results, res...

Editor's note: This story contains a description of self-harm. Oncologist Mark L...

EMA roundtable with stakeholders on the 20th anniversar...

EMA roundtable with stakeholders on the 20th anniversary of the SME Regulation, ...

J&J links FcRn blocker to sustained benefits as FDA rul...

Johnson & Johnson has reinforced a key plank of its plan to build nipocalimab in...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.